

Head Injury update Committee meeting 7

Date: 15/12/2021

Location: Virtual meeting

Minutes: Final

Committee members present:	
Caroline Balson [CB]	(Present for notes 1 – 8)
Ian Bernstein [IB] – Chair	(Present for notes 1 – 8)
Adel Helmy [AH]	(Present for notes 1 – 8)
Catriona Jones [CJ]	(Present for notes 1 – 8)
Fiona Lecky [FL] – Topic adviser	(Present for notes 1 – 8)
Virginia Newcombe [VN]	(Present for notes 1 – 8)
Patrick O’Halloran [PO]	(Present for notes 1 – 8)
James Piercy [JP]	(Present for notes 1 – 8)
Gillian Richards [GR]	(Present for notes 1 – 8)
Matthew Wiles [MW]	(Present for notes 1 – 8)
Colin Williamson [CW]	(Present for notes 1 – 8)

Co-opted members present:	
Barry Seemungal	Consultant Vestibular Neurologist, Imperial College Healthcare NHS Trust
Peta Sharples	Consultant Paediatric Neurologist, Bristol Royal Hospital for Children
Clara O’Brien	Consultant Clinical Neuropsychologist, University Hospitals Sussex NHS Foundation Trust
Indi Banerjee	Consultant in Paediatric Endocrinology, Royal Manchester Children’s Hospital

In attendance:		
Giulia Zuodar [GZ]	Project Manager	(Present for notes 1 – 8)
Sharangini Rajesh [SR]	Senior Research Fellow	(Present for notes 1 – 8)
Sharon Swain [SS]	Guideline Lead	(Present for notes 1 – 8)
David Wonderling [DW]	Head of Health Economics	(Present for notes 1 – 8)
Nicole Downes [ND]	Research Fellow	(Present for notes 1 – 8)

4.0.03 DOC Cmte minutes

Emma Clegg	Information Specialist	(Present for notes 7 – 8)
Helen Barnett [HB]	Senior Editor	(Present for notes 1 – 8)
Rupert Franklin [RF]	Guideline Commissioning Manager, NICE	(Present for notes 1 – 8)

Apologies:

Curtis Offiah [CO]	GC member
Emily Feilding [EF]	GC member
Mark Lyttle [ML]	GC member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the seventh meeting on Head Injury (update). Apologies were announced and are noted above.

The Chair outlined the objectives of the meeting, which included the following:

- Presenting the evidence for tranexamic for intracranial bleeding
- Presenting the evidence for biomarkers and MRI predicting post-concussion syndrome
- Finalising the protocols on admission and observation of people on anticoagulant therapy and on indications for hospital admission in small intracranial injuries

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was tranexamic for intracranial bleeding; biomarkers and MRI predicting post-concussion syndrome; admission and observation of people on anticoagulant therapy and indications for hospital admission in small intracranial injuries.

No new declarations were received.

3. Declarations of interest

The Chair and a senior member of the Developer's team confirmed that based on previously recorded declarations the following applies:

FL is partially excluded from the tranexamic acid review. FL can stay in the meeting

4.0.03 DOC Cmte minutes

but not participate in the recommendations.

FL, PO and VN are partially excluded from the biomarkers review. They can stay in the meeting but not participate in the recommendations.

4. Minutes of the previous meeting

The committee agreed that the minutes of the previous meeting were an accurate record of the meeting.

5. Evidence review: Tranexamic acid for intracranial bleeding

SR/DW gave a presentation on tranexamic acid for intracranial bleeding. The committee drafted recommendations.

6. Evidence review: Biomarkers and MRI predicting post-concussion syndrome

ND/DW gave a presentation on biomarkers and MRI predicting post-concussion syndrome. The committee drafted recommendations.

7. Protocols: Admission and observation of people on anticoagulant therapy and Indications for hospital admission in small intracranial injuries

SR presented the protocols on admission and observation of people on anticoagulant therapy and indications for hospital admission in small intracranial injuries. The GC made edits and signed off.

8. Any other business

None.

Date of next meeting: 15&16 February 2022

Location of next meeting: Virtual meeting